Abstract
The extensively investigated serine/threonine kinase, B-RAF, is a member of the RAS/RAF/MEK/ERK pathway. It plays important role in the regulation of cell growth, differentiation and survival. The mutation of B-RAF occurs frequently in melanomas and colon tumors; therefore, it is considered as an outstanding therapeutic target. In recent years a great number of B-RAF inhibitors have been reported and this number is expected to increase. The aim of our work was to compare the structures and binding mode of the published B-RAF inhibitors, and then to apply the correlations found for the explanation of our experimental results. In the first part of this paper we describe the main pharmacophore features of the co-crysallized B-RAF inhibitors published in the literature, focusing on the binding modes and common structural elements. In the second part we present and characterize our recently developed B-RAF inhibitor family by application of in silico methods and in vitro kinetic profiling. The inhibitory activity of these compounds was determined in biochemical kinase- and cell-based assays. The docking and assay results support our conclusion that the presented compound family belongs to the type I 1/2subgroup, they inhibit B-RAF and B-RAF(V600E) mutant in a sub-micromolar range and most of them show selectivity towards B-RAF(V600E) mutant expressing cell lines with equal or even better IC50 values than sorafenib.
Keywords: Binding mode, B-RAF, docking, kinase assay, kinase inhibitor, kinetic profiling.
Current Medicinal Chemistry
Title:Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors
Volume: 21 Issue: 17
Author(s): F. Baska, I. Szabadkai, A. Sipos, N. Breza, C. Szantai-Kis, L. Kekesi, R. Garamvolgyi, Z. Nemes, F. Baska, L. Neumann, R. Torka, A. Ullrich, G. Keri and L. Orfi
Affiliation:
Keywords: Binding mode, B-RAF, docking, kinase assay, kinase inhibitor, kinetic profiling.
Abstract: The extensively investigated serine/threonine kinase, B-RAF, is a member of the RAS/RAF/MEK/ERK pathway. It plays important role in the regulation of cell growth, differentiation and survival. The mutation of B-RAF occurs frequently in melanomas and colon tumors; therefore, it is considered as an outstanding therapeutic target. In recent years a great number of B-RAF inhibitors have been reported and this number is expected to increase. The aim of our work was to compare the structures and binding mode of the published B-RAF inhibitors, and then to apply the correlations found for the explanation of our experimental results. In the first part of this paper we describe the main pharmacophore features of the co-crysallized B-RAF inhibitors published in the literature, focusing on the binding modes and common structural elements. In the second part we present and characterize our recently developed B-RAF inhibitor family by application of in silico methods and in vitro kinetic profiling. The inhibitory activity of these compounds was determined in biochemical kinase- and cell-based assays. The docking and assay results support our conclusion that the presented compound family belongs to the type I 1/2subgroup, they inhibit B-RAF and B-RAF(V600E) mutant in a sub-micromolar range and most of them show selectivity towards B-RAF(V600E) mutant expressing cell lines with equal or even better IC50 values than sorafenib.
Export Options
About this article
Cite this article as:
Baska F., Szabadkai I., Sipos A., Breza N., Szantai-Kis C., Kekesi L., Garamvolgyi R., Nemes Z., Baska F., Neumann L., Torka R., Ullrich A., Keri G. and Orfi L., Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors, Current Medicinal Chemistry 2014; 21 (17) . https://dx.doi.org/10.2174/0929867321666140304152606
DOI https://dx.doi.org/10.2174/0929867321666140304152606 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circulating Aminopeptidase Activities in Men and Women with Essential Hypertension
Current Medicinal Chemistry Vacuolar H+-ATPase Signaling Pathway in Cancer
Current Protein & Peptide Science Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry Biology of Protooncogene c-kit Receptor and Spermatogenesis
Current Pharmacogenomics Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Current Pharmaceutical Design Physiology of Folic Acid in Health and Disease
Current Drug Metabolism Editorial [Hot Topic: Pharmacogenomics: Achievements, Challenges and Prospects, for Patients, Pharmaceutical Industries and Healthcare Systems (Guest Editor: Despina Sanoudou)]
Current Pharmaceutical Design Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Letters in Drug Design & Discovery Alternative Approaches to the Discovery and Development of Telomerase- Targeted Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Acridone-based Antitumor Agents: A Mini-review
Anti-Cancer Agents in Medicinal Chemistry Cellular Targets for Anticancer Strategies
Current Drug Targets Differences and Similarities of Epothilones
Current Cancer Therapy Reviews Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Polymeric Nano-Encapsulation of Curcumin Enhances its Anti-Cancer Activity in Breast (MDA-MB231) and Lung (A549) Cancer Cells Through Reduction in Expression of HIF-1α and Nuclear p65 (Rel A)
Current Drug Delivery ADAM-Integrin Interactions: Potential Integrin Regulated Ectodomain Shedding Activity
Current Pharmaceutical Design Tumor Systems Need to be Rendered Usable for a New Action-Theoretical Abstraction: The Starting Point for Novel Therapeutic Options
Current Cancer Therapy Reviews Synthesis of Methotrexate Loaded Chitosan Nanoparticles and in vitro Evaluation of the Potential in Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Evaluation on Auto-segmentation of the Clinical Target Volume (CTV) for Graves' Ophthalmopathy (GO) with a Fully Convolutional Network (FCN) on CT Images
Current Medical Imaging Targeting Invasion Induction as a Therapeutic Strategy for the Treatment of Cancer
Current Cancer Drug Targets